Animal model and therapeutic prospects for left ventricular hypertrophy and associated renal complication
A. Ahmad, Z. Riaz, M. A. Sattar, S. A. Khan, E. J. John, S. Arshad, S. T. A. Shah, M. A. Rafiq, R. Qamar, M. Azam
Abstract
Cardiac and renal dysfunction often co-occur and considerably worsen the prognosis leading to difficulty in therapy in left ventricular hypertrophy (LVH). The aim of this study was to elucidate changes in expression of human ortholog genes of hypertension, vascular and cardiac remodeling and hypertensive nephropathy phenotypes under normal, disease and gasotransmitter, H2S (hydrogen sulphide) and NO (nitric oxide) and combined (H2S+NO), treatment of rat myocardium and renal tissues. LVH rat models were generated and were treated with H2S and NO. Relative gene expression was quantified. Heart and renal physical indices were significantly modified under individual as well as combined H2S+NO treatment in control and LVH rats. Expression analysis revealed, hypertension, vascular remodeling genes ACE, TNF and IGF1, mRNAs to be significantly increased (P<0.05) in myocardia and kidneys of LVH rats, while individual and combined H2S+NO treatment reduced gene expression to normal/near to normal values. The cardiac remodeling genes MYH7, TGF{beta}, SMAD4 and BRG1 expression were significantly up-regulated (P<0.05) in the myocardia of LVH and combined H2S+NO treatment, which recovered the normal/near to normal expression more effectively as compared to individual treatments. Interestingly, individual as well as combined H2S and NO treatment significantly decreased PKD1 expression in renal tissue, which was significantly up-regulated in LVH rats (P<0.05). The reduction in hemodynamic parameters and cardiac indices as well as alteration in gene expression on treatment in LVH rat model indicates important therapeutic potential of combined treatment with H2S+NO gasotransmitters in hypertension and cardiac hypertrophy associated with renal complications.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Role of microRNA-21 in hypertrophic cardiac remodeling
Ken Watanabe, Taro Narumi, … Masafumi Watanabe·PLoS ONEPeer-reviewed·Feb 10, 2020
- Cellular Interplay and Cytokine Hierarchy Cause Pathological Cardiac Hypertrophy in RAF1-Mutant Noonan Syndrome
J. C. Yin, M. J. Platt, … B. G. Neel·bioRxiv·Mar 30, 2017
- The Ca2+-activated cation channel TRPM4 is a positive regulator of pressure overload-induced cardiac hypertrophy
Y. Guo, J. Yu, … B. Martinac·bioRxiv·Dec 21, 2020
- Normalizing LZ+ MYPT1 Expression Prevents the Development of HFpEF
Young Soo Han, Teresa M. Pfiefer, … Frank V. Brozovich·bioRxiv·Aug 25, 2026
- Dynamic Fluoroleucine PET Detects Impaired Cardiac Leucine Uptake Before Hypertensive Left Ventricular Hypertrophy Develops
William Terrell, Jie Li, … Bijoy Kundu·bioRxiv·May 14, 2026
- Histopathological Effects of Therapeutic Doses of Combined XO-Inhibitors and ACE-Inhibitors on the Expression of VEGF-A in the Myocardium and Renal Cortex in Chronic Hypertensive Albino Rats
Hassan M. Rezk, Afaf Ibraheim·bioRxiv·Jul 15, 2017